Core Viewpoint - The IPO application of Qichacha Technology Co., Ltd. has been accepted, aiming to raise 1.5 billion RMB despite having substantial cash reserves and low liabilities, raising questions about the necessity of the fundraising [1][2][6]. Financial Position - Qichacha has over 1.7 billion RMB in broad monetary funds, with more than 75% of its assets in financial products, indicating a strong liquidity position [2][6]. - The company has almost zero interest-bearing debt, with short-term and long-term borrowings reported as zero [3][6]. - Revenue and net profit figures for 2022 to mid-2025 show consistent growth, with revenues of 5.18 billion RMB in 2022, 6.18 billion RMB in 2023, and 7.08 billion RMB in 2024, alongside net profits of 1.9 billion RMB, 2.59 billion RMB, and 3.17 billion RMB respectively [6][7]. IPO Details - The IPO plans to issue up to 40.25 million shares, representing 10% of the total post-issue share capital, with the raised funds allocated to various R&D projects [2][7]. - Approximately 40% of the raised funds will be used for personnel investments across different projects, indicating a significant focus on human resources in the development process [7]. Underwriting Concerns - The underwriting firm, CITIC Securities, has raised concerns regarding its independence, as its subsidiary invested in Qichacha shortly before the underwriting agreement was signed [8][10]. - The lack of disclosed pricing for the subsidiary's investment raises questions about transparency and valuation changes [11][12]. R&D Expenditure - Qichacha's R&D expense ratio is significantly lower than its peers, with rates of 18.02% in 2022, 17.45% in 2023, and 16.05% in the first half of 2025, compared to an average of 24.19% among comparable companies [15][16][17]. - The company claims that its R&D expenditure is within a reasonable range compared to competitors, despite being notably lower, which may impact its technological competitiveness in the rapidly evolving commercial big data service industry [17].
企查查IPO:募资必要性存疑 研发费用率显著低于同行 保荐券商“既当裁判又当选手”
Xin Lang Zheng Quan·2025-10-13 09:30